Biomarin Pharmaceutical

🇨🇦Canada
Ownership
-
Established
1997-01-01
Employees
-
Market Cap
$17.2B
Website
http://www.biomarin.com
benzinga.com
·

Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry

AbbVie, a pharmaceutical firm with strong immunology and oncology portfolios, is compared against key competitors in the Biotechnology industry. The analysis reveals AbbVie's high Price to Earnings (64.53), Price to Book (50.28), and Price to Sales (6.22) ratios, suggesting a potentially overvalued stock. However, its high Return on Equity (18.4%), EBITDA ($5.0B), and gross profit ($10.26B) indicate strong profitability and operational efficiency. The company's low revenue growth (4.31%) compared to the industry average (28.79%) raises concerns about future performance.
globenewswire.com
·

Gene Therapy Market Report 2024-2035, by Therapeutic Area

The Global Gene Therapy Market is valued at USD 2.4 billion in 2024, growing at a CAGR of 19.25% during 2024-2035. Gene therapies aim to treat genetic disorders by introducing healthy genes or inactivating faulty ones. The market has seen significant advancements, with 345 companies involved in developing therapies, and 1,100 active clinical trials in April 2024. By 2034, gene therapies are expected to treat over 65.6 million patients.
benzinga.com
·

Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry

Regeneron Pharmaceuticals' PE, PB, and PS ratios are low, suggesting potential undervaluation. However, its low ROE indicates lower profitability. High EBITDA and gross profit levels indicate strong financial performance, but low revenue growth may be a concern.
© Copyright 2024. All Rights Reserved by MedPath